Loading…
← CockpitCompetitor Analysis › 9877.HK Jenscare Scientific Co. Ltd. Class HOpen in the cockpit ↗

Jenscare Scientific Co. Ltd. Class H9877.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical Specialties
Momentum weak 26
Mkt cap
$415M
US dollars, full cap
Free float
44%
of shares outstanding
$/day
$89,314
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-43.4 pp
WACC 8.1%
Hurdle
n/a
no reverse DCF
Next earnings
133 days
31 Mar 2027
Close · HKDHK$5.76
1D+2.1%
1W-7.8%
1M-16.5%
3M-22.9%
6M-32.2%
YTD-35.3%
1Y-44.6%
ATR %7.3%
52w lowhigh45.2% off high

What Jenscare Scientific does

Employees: 195

Jenscare Scientific at a glance

Size Jenscare Scientific (9877.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $415M, the 792nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$5.76 on 18 Nov 2026.

Performance Over six months the shares fell 32.2%, against -19.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 992.7% over the last twelve months (peer median +7.3%); the operating margin is -106.3% (peer median 8.1%).

Valuation It trades at 17.8× enterprise value to sales against a peer median of 3.9× (most expensive of 19).

Capital Return on invested capital runs 43.4 points below its cost of capital (8.1% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 809877.HK 68
Six months, rebased to 100: Jenscare Scientific against the median of its 20 peers (local-currency closes).

Jenscare Scientific financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$158MHK$98.2MHK$0HK$0HK$0
Revenue growth—————
Gross profitHK$121MHK$74.6M-HK$13.9M-HK$13.3M-HK$10.7M
EBITDA-HK$147M-HK$242M-HK$222M-HK$471M-HK$584M
Net income-HK$167M-HK$294M-HK$192M-HK$411M-HK$511M
Free cash flow-HK$84.6M-HK$86.2M-HK$313M-HK$332M-HK$247M
Capital expenditureHK$17.6MHK$5.50MHK$77.7MHK$86.9MHK$57.6M
Total debtn/aHK$52.8MHK$68.6MHK$48.5MHK$4.35M

Quarterly statements and history in the cockpit →

Jenscare Scientific competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-10%0%+10%3010976883583005156881331763REG1VSIMOBIMASS6880266929458870300110CERS002022CU647366039870020169877.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Jenscare Scientific is the large dot.

Fundamentals: revenue growth against valuation

0%+250%+500%+750%+1,000%0×5×10×15×301097688358300515688133SI300238MOBI6929458870CERS9877.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jenscare Scientific is the large dot.

Jenscare Scientific competitors and peer comparison

How Jenscare Scientific compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jenscare Scientific against its 20 peers (data as of 18 Nov 2026)
Measure9877.HKPeer medianRank in peer set
1-month return-16.5%-10.5%3rd lowest of 21
6-month return-32.2%-19.4%5th lowest of 21
Distance from 52-week high-45.2%-36.0%9th lowest of 21
Revenue growth (TTM)+992.7%+7.3%highest of 20
Operating margin-106.3%8.1%2nd lowest of 20
EV / Sales17.8×3.9×most expensive of 19
ROIC minus cost of capital-43.4 pp-2.1 pp2nd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Jenscare Scientific 9877.HKHong Kong$415M-32%+993%-106%17.8×n/an/a
Ningbo Tianyi Medical Appliance 301097.SZChina$418M-22%+46%8%4.4×n/an/a
Chison Medical Technologies 688358.SSChina$406M-27%-1%19%3.9×9.6%+5.6%
Hunan Sundy Science and Technology 300515.SZChina$425M-16%+10%27%3.5×-0.1%+15.6%
Shanghai Titan Scientific 688133.SSChina$403M-26%+1%-6%1.4×n/an/a
China Isotope & Radiation 1763.HKHong Kong$428M-41%-5%13%n/an/an/a
Revenio REG1V.HEFinland$428M-34%+44%10%4.0×18.5%+12.4%
Shoulder Innovations SIUnited States$432M+39%+55%-54%5.5×n/an/a
Guanhao Biotech 300238.SZChina$397M-26%-12%3%7.1×n/an/a
Mobia Medical MOBIUnited States$434M+2%+105%-145%8.8×n/an/a
908 Devices MASSUnited States$396M+36%+14%-33%4.6×41.7%+15.9%
Guangzhou Jet Bio-Filtration 688026.SSChina$436M+39%+5%11%4.8×20.6%+2.2%
OrbusNeich Medical 6929.HKHong Kong$394M-15%+16%23%1.0×-17.6%+15.4%
SEERS 458870.KSSouth Korea$392M-70%+174%37%5.5×-6.3%+247.0%
Huaren Pharmaceutical 300110.SZChina$440M-16%-3%6%3.3×5.8%+0.3%
Cerus CERSUnited States$392M-28%+14%-12%1.8×n/an/a
Shanghai Kehua Bio-Engineering 002022.SZChina$389M-14%+7%-40%1.7×n/an/a
Clarity Pharmaceuticals CU6.AXAustralia$444M-33%n/an/an/an/an/a
Taidoc Technology 4736.TWTaiwan$387M0%0%19%1.8×-9.5%-6.6%
Shanghai Kindly Enterprises Development 603987.SSChina$452M-12%0%10%1.5×-1.0%-2.8%
Guangdong Shirongzhaoye 002016.SZChina$453M-26%-31%3%3.8×21.5%-11.7%

Questions

Which companies are Jenscare Scientific's closest peers?
The cockpit's peer set: Ningbo Tianyi Medical Appliance (301097.SZ), Chison Medical Technologies (688358.SS), Hunan Sundy Science and Technology (300515.SZ), Shanghai Titan Scientific (688133.SS), China Isotope & Radiation (1763.HK), Revenio (REG1V.HE), Shoulder Innovations (SI), Guanhao Biotech (300238.SZ).
Is Jenscare Scientific expensive compared with its peers?
On ev / sales it trades at 17.8× against a peer median of 3.9×, most expensive of 19 in its peer set.
How has Jenscare Scientific stock performed?
Over six months to 18 Nov 2026 the shares returned -32.2% against -19.4% for the median peer; over one year -44.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.